How is glargine different from NPH insulin?

Glargine has a flatter, longer action profile, and randomized trials show it generally causes less nocturnal hypoglycemia than NPH at similar glucose control.

Does insulin glargine cause heart problems?

In the large ORIGIN trial, glargine-based glucose targeting was cardiovascular-neutral compared with standard care. It neither clearly raised nor lowered cardiovascular events.

What is the biggest safety risk?

Hypoglycemia (low blood sugar), which can become severe. It requires blood-glucose monitoring and a clinician-set dose, and is more likely with missed meals, exercise, or tight targets.

Can different insulin glargine products be swapped one-for-one?

No. Concentrated forms like U-300 are not unit-for-unit interchangeable with U-100, and any switch should be made only under medical supervision.

EMA-approvedaka Lantus, Toujeo, Basaglar, Semglee

Insulin glargine — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Insulin glargine (also known as Lantus) is a peptide catalogued under Hormones & Metabolic (Long-acting insulin analogue). It is described as: Insulin receptor agonist. Documented context: Diabetes mellitus. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Insulin glargine?

Insulin glargine is a long-acting recombinant human insulin analog, marketed as Lantus (and biosimilars and concentrated forms such as Toujeo). It is FDA- and EMA-approved as basal insulin for adults and children with type 1 diabetes and for adults with type 2 diabetes.

The evidence base is large and human, including active-comparator RCTs against NPH insulin and a cardiovascular-outcomes trial (ORIGIN).

How does Insulin glargine work?

Amino-acid substitutions shift the insulin's isoelectric point so it precipitates at physiologic pH after injection, then dissolves slowly to give a relatively flat, roughly 24-hour glucose-lowering profile.

This provides steady basal insulin coverage with less pronounced peaks than intermediate-acting NPH insulin.

What does the research say about Insulin glargine?

Added to oral therapy in type 2 diabetes, once-daily glargine achieved target fasting glucose with less symptomatic and nocturnal hypoglycemia than NPH insulin in the Treat-to-Target trial. ^[2]
A meta-analysis found glargine reduced the risk of hypoglycemia (including severe and nocturnal events) compared with NPH insulin in type 2 diabetes at similar glycemic control. ^[3]
In the ORIGIN cardiovascular-outcomes trial, targeting normal fasting glucose with glargine was cardiovascular-neutral versus standard care over a median of more than 6 years. ^[1]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Basal insulin and cardiovascular and other outcomes in dysglycemia — ORIGIN Trial Investigators, The New England Journal of Medicine 2012. (Randomized cardiovascular-outcomes trial)
[2] The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients — Riddle MC et al., Diabetes Care 2003. (Randomized controlled trial)
[3] Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes — Rosenstock J et al., Diabetes Care 2005. (Meta-analysis of randomized trials)
[4] Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes — Ratner RE et al., Diabetes Care 2000. (Randomized controlled trial)
[5] Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes — Yki-Jarvinen H et al., Diabetes Care 2000. (Randomized controlled trial)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Insulin glargine is a prescription injectable whose dose is highly individualized and titrated by a clinician against blood-glucose monitoring, and concentrated forms (such as U-300) are not unit-for-unit interchangeable with U-100.

This page is educational only and deliberately gives no dose; insulin errors can be life-threatening, so regimen, titration, and hypoglycemia management belong to a qualified healthcare team.

Side effects & safety profile

The main risk of any insulin, including glargine, is hypoglycemia, which can be severe; symptoms include sweating, tremor, confusion, and, if untreated, seizures or loss of consciousness.

Randomized data show glargine tends to cause less nocturnal hypoglycemia than NPH insulin, but the risk is not eliminated and rises with tighter targets, missed meals, or exercise.

Other considerations include weight gain, injection-site reactions, and the need to never mix or interchange insulin products without clinician guidance; dosing must be individualized to avoid dangerous highs or lows.

Stacking & combinations

In practice basal glargine is combined with mealtime (bolus) insulin or oral/GLP-1 agents under medical supervision, not self-adjusted, because layered glucose-lowering drugs sharply increase hypoglycemia risk.

Finding Insulin glargine vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is a long-acting basal insulin approved for type 1 diabetes and for type 2 diabetes, providing background insulin coverage across about 24 hours.

References

[1] Basal insulin and cardiovascular and other outcomes in dysglycemia — ORIGIN Trial Investigators, The New England Journal of Medicine 2012. PMID: 22686416. View sourceStudy: Randomized cardiovascular-outcomes trialGlargine-based normoglycemia targeting was cardiovascular-neutral versus standard care in people with dysglycemia.
[2] The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients — Riddle MC et al., Diabetes Care 2003. PMID: 14578243. View sourceStudy: Randomized controlled trialGlargine reached target fasting glucose with less symptomatic and nocturnal hypoglycemia than NPH.
[3] Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes — Rosenstock J et al., Diabetes Care 2005. PMID: 15793205. View sourceStudy: Meta-analysis of randomized trialsGlargine lowered hypoglycemia risk versus NPH at comparable glycemic control in type 2 diabetes.
[4] Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes — Ratner RE et al., Diabetes Care 2000. PMID: 10834423. View sourceStudy: Randomized controlled trialIn type 1 diabetes, glargine reduced nocturnal hypoglycemia versus NPH during intensive therapy.
[5] Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes — Yki-Jarvinen H et al., Diabetes Care 2000. PMID: 10937510. View sourceStudy: Randomized controlled trialBedtime glargine gave less nocturnal hypoglycemia and better post-dinner glucose than bedtime NPH.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.